Please note that only limited free access to this journal is available in your country or territory.

To access the full content of this article you must purchase it (US$9.49). After payment of this one-off fee, you will gain unrestricted online access to the article and a PDF version sent to your email.

As part of our special introductory offer, after purchasing this article you will have unrestricted access to all the articles in this issue for free!

Registered users can purchase/access the article by logging in below. To register for free click here

Registered users login here:

  • Email Address:
     
  • Password:
     
  •  
If you have forgotten your password click here
0 rating

Prostanoids

Oudiz RJ, Farber HW.

Harbor–UCLA Medical Center, Torrance, CA, USA.

 Am J Heart 2009;157:625–35.

Editor’s note: Epoprostenol was the first prostanoid to be approved for intravenous use in pulmonary arterial hypertension (PAH) by the US Food and Drug Administration in 1995. A later-developed prostanoid is trepostinil, which may be administered subcutaneously or intravenously. Although intravenous prostanoids remain the most effective treatment for PAH, there is a lack of comprehensive studies assessing their use in clinical practice. Therefore, the present authors evaluated epoprostenol and trepostinil in the treatment of PAH in terms of dosing and efficacy by reviewing the current literature, and also by means of a survey of US physicians who treat patients with PAH.

Please login or register to continue reading this article
Return to top
Login/Register

Post Page On

LATEST ARTICLES

Our most popular articles